Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Xetra  >  Carl Zeiss Meditec AG    AFX   DE0005313704

CARL ZEISS MEDITEC AG

(AFX)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Carl Zeiss Meditec : continues strong growth trend after nine months of 2018/19

share with twitter share with LinkedIn share with facebook
share via e-mail
0
08/12/2019 | 09:18am EDT

Revenue and earnings forecast for fiscal year 2018/19 further specified.

Carl Zeiss Meditec generated revenue of EUR1,027.6m in the first nine months of fiscal year 2018/19, corresponding to an increase of 10.9% (adjusted for currency effects: +8.9%) compared with the same period of the prior year (prior year: EUR926.3m). Earnings before interest and taxes (EBIT) increased significantly, to EUR184.2m (prior year: EUR134.8m). The EBIT margin also increased, to 17.9% (prior year: 14.6%).

'All strategic business units made valuable contributions to this very encouraging increase in revenue and earnings. Once again, revenue from consumables for ophthalmic surgery increased the most,' says Dr. Ludwin Monz, President and CEO of Carl Zeiss Meditec AG.

Ophthalmology and Microsurgery continue to grow

The Ophthalmic Devices strategic business unit (SBU) increased its revenue by 12.0 percent in the first nine months of fiscal year 2018/19 (adjusted for currency effects: +10.1 percent), to EUR762.7m, compared with EUR681.0m in the first nine months of fiscal year 2017/18. This revenue increase was mainly attributable to the persistently high demand for laser vision correction systems, as well as devices and consumables for cataract surgery.

Revenue in the Microsurgery SBU grew by 8.0 percent (adjusted for currency effects: +5.7 percent), to EUR264.9m, compared with EUR245.2m in the same period of the prior year. Sales of neurosurgical visualization systems for the treatment of tumors and vascular disease also remained buoyant.

Solid growth in EMEA and APAC

Revenue in the EMEA region rose by 9.3 percent in the first nine months of fiscal year 2018/19 (adjusted for currency effects: +10.0 percent), to EUR308.2m (prior year: EUR282.0m). Germany, France and the UK posted strong revenue growth.

Revenue in the Americas region amounted to EUR292.5m, and thus only approximated the prior year's level after adjustment for currency effects (prior year: EUR279.3m; equates to +4.7 percent, or after adjustment for currency effects, -0.3 percent). This development should mainly be viewed in the context of a strong prior-year period, which benefited significantly from new product launches.

Once again, the APAC region achieved the highest growth rate, with a revenue increase of 17.0 percent (adjusted for currency effects: +15.4 percent), to EUR426.9m (prior year: EUR364.9m). The largest contributions to this growth once again came from China and South Korea. Japan also performed well.

The operating result (EBIT) increased in the first nine months of the current fiscal year, reaching EUR184.2m (prior year: EUR134.8m). This growth is mainly due to a positive development of the product mix, with a high proportion of recurring revenue. The EBIT margin increased from 14.6 percent to 17.9 percent. Adjusted for special effects, this resulted in an increase to 18.2 percent (prior year: 14.8 percent). Earnings per share rose from EUR0.92 in the prior year to EUR1.22.

Based on this positive trend, Carl Zeiss Meditec is further specifying its forecast for fiscal year 2018/19. Revenue is expected to be at the upper end of or slightly above the previous forecast range of EUR1,350m to EUR1,420m. The EBIT margin is expected to exceed the corridor set in April 2019, of 15.0 to 17.5 percent, in the current fiscal year.

Dr. Ludwin Monz added: 'Our main objective is to increase our long-term competitiveness. As already communicated when we published our half-year results, we plan to capitalize on the current favorable earnings situation to also step up investments in research and development. This applies in particular to the area of digital solutions for ophthalmic surgery, in which we aim to further extend our innovative edge. We shall make a precise forecast for the development of the EBIT margin beyond the end of the current fiscal year when we publish our annual results for fiscal year 2018/19. From today's perspective, however, we do not anticipate a sustainable increase in the EBIT margin in fiscal year 2019/20, in view of the planned strategic investments.'

Revenue by strategic business unit

All figures in EURm

9 months

2018/19

9 months

2017/18

Change from

prior year

Change from

prior year*

Ophthalmic Devices

762.7

681.0

+12.0%

+10.1%

Microsurgery

264.9

245.2

+8.0%

+5.7%

Overall group

1,027.6

926.3

+10.9%

+8.9%

*adjusted for currency effects

Revenue by region

All figures in EURm

9 months

2018/19

9 months

2017/18

Change from

prior year

Change from

prior year*

EMEA

308.2

282.0

+9.3%

+10.0%

Americas

292.5

279.3

+4.7%

0.3%

APAC

426.9

364.9

+17.0%

+15.4%

Overall group

1,027.6

926.3

+10.9%

+8.9%

*adjusted for currency effects

Press Contact

Sebastian Frericks

Director Investor Relations

Carl Zeiss Meditec AG

Phone: +49 3641 220-116

investors.meditec@zeiss.com

Brief Profile

Carl Zeiss Meditec AG (ISIN: DE 0005313704), which is listed on the MDAX and TecDAX of the German stock exchange, is one of the world's leading medical technology companies. The Company supplies innovative technologies and application-oriented solutions designed to help doctors improve the quality of life of their patients. The Company offers complete solutions, including implants and consumables, to diagnose and treat eye diseases. The Company creates innovative visualization solutions in the field of microsurgery. With approximately 3,050 employees worldwide, the Group generated revenue of EUR1,280.9m in fiscal year 2017/18 (to 30 September).

The Group's head office is located in Jena, Germany, and it has subsidiaries in Germany and abroad; more than 50 percent of its employees are based in the USA, Japan, Spain and France. The Center for Application and Research (CARIn) in Bangalore, India and the Carl Zeiss Innovations Center for Research and Development in Shanghai, China, strengthen the Company's presence in these rapidly developing economies. Around 41 percent of Carl Zeiss Meditec AG's shares are in free float. The remaining approx. 59 percent are held by Carl Zeiss AG, one of the world's leading groups in the optical and optoelectronic industries.

For more information visit our website at www.zeiss.com/med

(C) 2019 Electronic News Publishing, source ENP Newswire

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on CARL ZEISS MEDITEC AG
08/12CARL ZEISS MEDITEC : continues strong growth trend after nine months of 2018/19
AQ
08/09EUROPE : Italy leads European shares lower on political uncertainty
RE
08/09GLOBAL MARKETS LIVE : Bayer, Huawei, Airbus, Occidental Petroleum…
08/09CARL ZEISS MEDITEC : continues strong growth trend after nine months of 2018/19
EQ
08/02CARL ZEISS MEDITEC AG : Preliminary announcement of the publication of quarterly..
EQ
07/16INFORMATION PURSUANT : Carl Zeiss Meditec is aiming for the upper end of its rev..
PU
07/15CARL ZEISS MEDITEC : is aiming for the upper end of its revenue forecast for the..
EQ
06/19EUROPE : European stocks tread water, all eyes on Fed
RE
06/18A pivotal month of June
06/04A war on all fronts
More news
Financials (EUR)
Sales 2019 1 428 M
EBIT 2019 264 M
Net income 2019 168 M
Finance 2019 665 M
Yield 2019 0,64%
P/E ratio 2019 54,7x
P/E ratio 2020 46,7x
EV / Sales2019 6,00x
EV / Sales2020 5,46x
Capitalization 9 239 M
Chart CARL ZEISS MEDITEC AG
Duration : Period :
Carl Zeiss Meditec AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CARL ZEISS MEDITEC AG
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 10
Average target price 92,38  €
Last Close Price 103,40  €
Spread / Highest target -3,29%
Spread / Average Target -10,7%
Spread / Lowest Target -20,7%
EPS Revisions
Managers
NameTitle
Ludwin Monz President & Chief Executive Officer
Michael Kaschke Chairman-Supervisory Board
Justus Felix Wehmer Chief Financial Officer
Markus Guthoff Member-Supervisory Board
Cornelia Grandy Member-Supervisory Board
Sector and Competitors
1st jan.Capitalization (M$)
CARL ZEISS MEDITEC AG51.24%10 165
THERMO FISHER SCIENTIFIC32.41%118 673
DANAHER CORPORATION42.04%105 073
INTUITIVE SURGICAL10.91%61 218
BOSTON SCIENTIFIC CORPORATION22.50%60 302
EDWARDS LIFESCIENCES CORPORATION43.41%45 683